1. Home
  2. LAUR vs CRSP Comparison

LAUR vs CRSP Comparison

Compare LAUR & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Laureate Education Inc.

LAUR

Laureate Education Inc.

HOLD

Current Price

$33.68

Market Cap

4.6B

Sector

Real Estate

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$57.26

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAUR
CRSP
Founded
1989
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
4.9B
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
LAUR
CRSP
Price
$33.68
$57.26
Analyst Decision
Buy
Buy
Analyst Count
4
17
Target Price
$39.63
$70.29
AVG Volume (30 Days)
974.5K
1.5M
Earning Date
04-30-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,484,288,000.00
$289,590,000.00
Revenue This Year
$14.58
$807.72
Revenue Next Year
$7.85
$172.52
P/E Ratio
N/A
N/A
Revenue Growth
19.48
9169.85
52 Week Low
$21.16
$39.81
52 Week High
$37.91
$78.48

Technical Indicators

Market Signals
Indicator
LAUR
CRSP
Relative Strength Index (RSI) 57.17 60.77
Support Level $33.10 $50.72
Resistance Level $34.46 $60.29
Average True Range (ATR) 0.98 2.51
MACD 0.10 0.49
Stochastic Oscillator 73.14 84.77

Price Performance

Historical Comparison
LAUR
CRSP

About LAUR Laureate Education Inc.

Laureate Education Inc is an international community of universities. The company provides higher education programs and services to students through an international network of licensed universities and higher education institutions. Its reportable segments include Peru and Mexico, of which Mexico derives maximum revenue. Geographically, the company operates in Mexico, Peru and United States.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: